The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy

Current Opinion in Lipidology

Volumn 25, Issue 4, 2014, Pages 239-246

  Soran, Handrean ^a   Schofield, Jonathan D ^a   Durrington, Paul N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

absolute CVD risk; LDL cholesterol; number needed to treat; population impact of statin therapy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CALCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; HYPERLIPIDEMIA; NUMBERS NEEDED TO TREAT; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

EID: 84904196120     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000097     Document Type: Review

References (37)

1. Cholesterol Treatment Trialists (CTT) Collaboration, Writing committee, Collaboration. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
2. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 2010; 340:c2197. doi: 10.1136/bmj. c2197.
3. Ara R, Basarir H, Ward SE. Principles of health economic evaluations of lipidlowering strategies. Curr Opin Lipidol 2012; 23:271-281.
4. Cholesterol Treatment Trialists' (CTT) Collaboration, Writing Committee. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: Meta-analysis of individual data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
5. Kizer JG, Madias C, Wilner B, et al. Relation of different measures of lowdensity lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol 2010; 105:1289-1296.
6. Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation 2013; 128:1504-1512.
7. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003; 326:1423-1427.
8. National Institute for Health and Clinical Excellence (NICE) clinical guideline 67. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Developed by the National Collaborating Centre for Primary Care. Issue date: May 2008 (reissued March 2010) http://www.nice.org.uk/ nice media/pdf/CG67NICEguideline.pdf.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
10. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
11. Wood DA, Wray R, Poulter N, et al. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl V):v1-52.
12. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14:32-38.
13. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guidance on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 160:339-343.
14. Statins for millions. [editorial], Lancet 2014; 383:669.
15. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2):293-298.
16. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of QRISK2. BMJ 2008; 336:1475-1482.
17. Ogden L, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35:539-543.
18. Ward S, Lloyd Jones S, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11:1-160; no 4.
19. van Kempen BJ, Ferket BS, Hofman A, et al. Do different methods of modeling statin treatment effectiveness influence the optimal decision? Med Decis Making 2012; 32:507-516.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled, trial. Lancet 2002; 360:7-22.
21. Martin SS, Metkus TS, Horne A, et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol 2012; 110:307-313.
22. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease.Am J Cardiol 2004; 94:20-24.
23. Liew SM, Jackson R, Mant D, Glasziou P. Should identical CVD risks in young and old patients be managed identically? Results from two models. BMJ 2012; 2:e000728.
24. Chaudhury M. Blood analytes. In: Sproston K, Primatesta P, editors. Health Survey for England 2003. Risk factors for cardiovascular disease. Vol 2. London: The Stationery Office; 2004. pp. 241-287.
25. van Wijk DF, Boekholdt SM, Wareham NJ, et al. C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. Arterioscler Thromb Vasc Biol 2013; 33:2888-2894.
26. Neil HA, Mant D, Jones L, et al. Lipid screening: Is it enough to measure total cholesterol concentration? BMJ 1990; 301:584-587.
27. Law MR, Wald NJ, Wu T, et al. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: Data from the BUPA study. BMJ 1994; 308:363-366.
28. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150:341-353.
29. Emberson JR, Whincup PH, Morris RW, Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: Impact of regression dilution bias. Eur Heart J 2003; 24:1719-1726.
30. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. Lancet 1986; 2:933-936.
31. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
32. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-372.
33. Lewington S,Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370:1829-1839.
34. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303:276-282.
35. Steinberg D. Thematic review series: The pathogenesis of atherosclerosis: An interpretive history of the cholesterol controversy, part III: Mechanistically defining the role of hyperlipidemia. J Lipid Res 2005; 46:2037-2051.
36. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower lowdensity lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. J Am Coll Cardiol 2012; 60:2631-2639.
37. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J 2008; 29:2625-2633.